News Archive

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit in taking metformin at a titrated dosage of 1,500 mg per day for 14 days for the treatment of mild-to-moderate COVID-19 symptoms.

The Duke Clinical Research Institute (DCRI) has launched its new podcast, "Beyond the Endpoint," aimed at demystifying clinical research and healthcare through engaging conversations with renowned clinicians and scientists. The podcast debuted on Wednesday, Jan. 15, and provides personal and expert perspectives on the latest gold-standard research and real-world evidence, making complex topics accessible to a broad audience.

Cytokinetics, Incorporated today announced that COMET-HF (Confirmation of O

i-Cubed, Duke Clinical Research Institute’s (DCRI) center for clinical research innovation, is partnering with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for BARDA’s Decentralized Clinical Operations for Healthcare and Research (D-COHRe) program to enhance decentralized clinical trial (DCT) capabilities to address public health emergencies (PHEs).

Faculty experts from the Duke Clinical Research Institute shared new research results, provided thought-provoking insights, and championed therapeutic guidelines and best practices as part of more than 40 sessions during the 2024 American Heart Association (AHA) Scientific Sessions.

Duke Clinical Research Institute (DCRI) faculty member Laura Schanberg, MD, was recently honored with the American College of Rheumatology (ACR) Master Designation during the College’s annual meeting, Convergence, 2024. The honor is an Award of Merit from the Association of Rheumatology Professionals (ARP) and reflects Schanberg’s outstanding contributions to the advancement of rheumatology.

Some 37 million people in the U.S. – more than one in seven adults – have chronic kidney disease (CKD). But not everyone faces the same risk. A new research consortium led by the Duke Clinical Research Institute and the Samuel DuBois Cook Center on Social Equity focuses on addressing the striking disparities in kidney health linked to structural racism.

Currently serving as commissioner of the Food and Drug Administration, Dr. Robert Califf is a Duke alumnus and renowned cardiologist who has held prominent leadership roles at Duke including founding director of the Duke Clinical Research Institute. In this interview with Dr. Adrian Hernandez, Vice Dean and Executive Director of the Duke Clinical Research Institute, Dr. Califf talks about his life, his mentors, and the emergence of data-drive research.

The American Heart Association's (AHA) Council on Quality of Care and Outcomes Research (QCOR) Council bestowed the Outstanding Lifetime Achievement Award on Adrian Hernandez, MD, MHS, the executive director of the Duke Clinical Research Institute (DCRI) and vice dean at the Duke University School of Medicine, during the AHA Scientific Sessions on November 16. The award is presented annually at the AHA Scientific Sessions to a QCOR Council member for their significant long-term contributions to outcomes research and the improvement of cardiovascular care.

Healthcare leaders have united to tackle the mounting challenges of expensive and inefficient drug development in an era of rising healthcare costs and aging populations. Their recommendations, published in the Journal of Clinical and Translational Science, chart a path toward more equitable, efficient, and inclusive clinical trials that better serve diverse communities.